Larimar Therapeutics, Inc.
NGM: LRMRLive Quote
📈 ZcoreAI Score
Our AI model analyzes Larimar Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get LRMR Z-Score →About Larimar Therapeutics, Inc.
Healthcare
Biotechnology
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
📊 Fundamental Analysis
Larimar Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -132.6%, which indicates that capital utilization is currently under pressure.
At a current price of $4.85, LRMR currently sits at the 67th percentile of its 52-week range (Range: $1.73 - $6.42).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$503.83M
Trailing P/E
--
Forward P/E
-2.69
Beta (5Y)
1.02
52W High
$6.42
52W Low
$1.73
Avg Volume
4.33M
Day High
Day Low